As per this study, the Global Plasma Protein Therapeutic Market was valued USD XX MN (by revenue) in 2019 and is anticipated to reach USD XX MN by 2026 with a CAGR of XX%.
Plasma protein therapeutic comprises of plasma-derived and recombinant analog therapies. These involve the treatment of various rare, life-threatening, chronic and genetic diseases. Some of the diseases that can be treated by using plasma protein therapeutic include bleeding disorders, immune deficiencies, pulmonary disorders, neurological disorders, shock and trauma, liver cirrhosis and infectious diseases such as tetanus, hepatitis, and rabies. Immunoglobulins, albumin, coagulation factors, and alpha-1 proteinase inhibitor are types of plasma protein therapeutic.
The increasing applications of plasma proteins in the pharmaceutical industry are driving market growth. Additionally, growing expenditure in the healthcare industry along with the introduction of new plasma-based therapies is further fuelling market growth. On the other hand, slower approval procedure and implementation of stringent regulation policies may restrict market growth. Whereas, increasing demand for plasma-based therapies in emerging economies is expected to create potential opportunity during the forecast period.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of plasma protein therapeutic.
The broad plasma protein therapeutic market has been sub-grouped into type and application. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
- Coagulation Factors
- Alpha-1 proteinase inhibitor
- Primary Immunodeficiency Disorder
- Idiopathic Thrombocytopenic Purpura
- Secondary Immunodeficiency
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for plasma protein therapeutic in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Plasma Protein Therapeutic Market Share by Region (Representative Graph)
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the plasma protein therapeutic market include Baxter, Biotest, Chengdu Inst., China Biologics, CSL Behring, Grifols, Kedrion, Octapharma, and Shire Plc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.